一种用于人类和动物疫苗的新型组合佐剂平台
本文介绍了一种新型组合佐剂平台TriAdj,由TLR激动剂(polyI:C或CpG寡脱氧核苷酸)、宿主防御肽和聚膦腈三部分组成。该平台在小鼠、棉鼠、猪、羊和考拉等多种动物及人类候选疫苗中稳定且高效,可诱导有效的长期体液和细胞免疫,适用于母体免疫,在新生动物中即使存在母体抗体也高效。
要点
- TriAdj由TLR激动剂、宿主防御肽和聚膦腈三组分构成。
- 该平台在多种动物及人类候选疫苗中稳定且高效。
- TriAdj可诱导长期体液和细胞免疫,适用于母体免疫和新生儿。
核心结论
- 这种新型疫苗平台为当前和未来针对多种传染原的疫苗以及应对挑战性人群提供了良好机会。
研究设计与样本
- 本文为综述,检索范围未报告。
主要发现
- TriAdj平台在小鼠、棉鼠、猪、羊和考拉中测试的多种动物和人类疫苗中稳定且高效。
- TriAdj与各种疫苗抗原可诱导有效的长期体液和细胞免疫。
- 该佐剂平台适用于母体免疫,在新生动物中即使存在母体抗体也高效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvants are crucial components of many vaccines. They are used to improve the immunogenicity of vaccines with the aim of conferring long-term protection, to enhance the efficacy of vaccines in newborns, elderly or immunocompromised persons, and to reduce the amount of antigen or the number of doses required to elicit effective immunity. Novel combination adjuvants have been tested in both candidate animals and humans vaccines and have generated encouraging results. Recently, we developed a combination adjuvant platform (TriAdj) comprising of three components, namely a TLR agonist, either polyI:C or CpG oligodeoxynucleotides (ODN), host defense peptide and polyphosphazene. This adjuvant platform is stable and highly effective in a wide range of animal and human vaccines tested in mice, cotton rats, pigs, sheep, and koalas. TriAdj with various vaccines antigens induced effective long-term humoral and cellular immunity. Moreover, the adjuvant platform is suitable for maternal immunization and highly effective in neonates even in the presence of maternal antibodies. This novel vaccine platform, offers excellent opportunity for use in present and future generations of vaccines against multiple infectious agents and targets challenging populations.
引用
- Garg R, Babiuk L, van Drunen Littel-van den Hurk S, et al. A novel combination adjuvant platform for human and animal vaccines. Vaccine. 2017. PMID: 28599794. doi:10.1016/j.vaccine.2017.05.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。